TG Therapeutics Files 2024 10-K
Ticker: TGTX · Form: 10-K · Filed: Mar 3, 2025 · CIK: 1001316
Sentiment: neutral
Topics: 10-K, financials, biotech
TL;DR
TG Therapeutics 2024 10-K filed. Assets $155.8M, Liabilities $151.4M. Focus on B-cell cancer drugs.
AI Summary
TG Therapeutics, Inc. filed its 2024 10-K on March 3, 2025, reporting its fiscal year ending December 31, 2024. The company's financial statements show total assets of $155.8 million and total liabilities of $151.4 million for the year ended December 31, 2024. TG Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel treatments for B-cell malignancies.
Why It Matters
This filing provides a comprehensive overview of TG Therapeutics' financial health and operational status for the fiscal year 2024, crucial for investors assessing the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The company operates in the highly regulated and competitive biopharmaceutical industry, with significant research and development costs and clinical trial risks.
Key Numbers
- $155.8B — Total Assets (As of December 31, 2024)
- $151.4B — Total Liabilities (As of December 31, 2024)
- 10.04% — Incremental Borrowing Rate (Used for operating leases prior to Feb 28, 2019)
- 190,000,000 — Common Stock Shares Outstanding (As of December 31, 2024)
- 175,000,000 — Common Stock Shares Outstanding (As of March 3, 2025)
Key Players & Entities
- TG THERAPEUTICS, INC. (company) — Filer
- 2024 (date) — Fiscal Year End
- March 3, 2025 (date) — Filing Date
- $155.8 million (dollar_amount) — Total Assets (Dec 31, 2024)
- $151.4 million (dollar_amount) — Total Liabilities (Dec 31, 2024)
FAQ
What were TG Therapeutics' total revenues for the fiscal year ended December 31, 2024?
The provided text does not explicitly state the total revenues for the fiscal year ended December 31, 2024. It focuses on asset and liability figures.
What is the company's primary focus in terms of drug development?
TG Therapeutics, Inc. is focused on the development of novel treatments for B-cell malignancies.
When was the 10-K filing submitted?
The 10-K filing was submitted on March 3, 2025.
What was the incremental borrowing rate used for operating leases prior to February 28, 2019?
The incremental borrowing rate used for operating leases that commenced prior to February 28, 2019, through December 31, 2021, was 10.25%.
What were the total assets and liabilities as of December 31, 2024?
As of December 31, 2024, TG Therapeutics, Inc. reported total assets of $155,836,256 and total liabilities of $151,424,289.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 3, 2025 regarding TG THERAPEUTICS, INC. (TGTX).